Company Update: Pfizer Inc (NYSE:PFE) – Pfizer Announces Positive Top-Line Results from Two Phase 3 Trials of Tofacitinib in Adults with Moderate-to-Severe Chronic Plaque Psoriasis

[Business Wire] – Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials Program, OPT Pivotal #1 and OPT Pivotal #2 , evaluating the efficacy . . . → Read More: Company Update: Pfizer Inc (NYSE:PFE) – Pfizer Announces Positive Top-Line Results from Two Phase 3 Trials of Tofacitinib in Adults with Moderate-to-Severe Chronic Plaque Psoriasis Similar Articles: Pfizer Inc (NYSE:PFE) – Pfizer Invites Public to Listen to Webcast of April 24 Annual Meeting of Shareholders Market Update (NYSE:PFE): Pfizer Launches 2013 Integrated Annual Review Pfizer Inc (NYSE:PFE) – Pfizer Announces FDA Approval to Include Radiographic Data on Reduction of Progression of Structural Joint Damage for Adults with Moderately to Severely Active Rheumatoid Arthritis in Labeling for XELJANZ® (tofacitinib citrate)